David G. Warnock
#129,483
Most Influential Person Now
David G. Warnock's AcademicInfluence.com Rankings
David G. Warnockphilosophy Degrees
Philosophy
#6235
World Rank
#9237
Historical Rank
Logic
#3419
World Rank
#4573
Historical Rank
Download Badge
Philosophy
Why Is David G. Warnock Influential?
(Suggest an Edit or Addition)David G. Warnock's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury (2007) (6290)
- Liddle's syndrome: heritable human hypertension caused by mutations in the β subunit of the epithelial sodium channel (1994) (1096)
- Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. (2012) (831)
- Agalsidase-Beta Therapy for Advanced Fabry Disease (2007) (486)
- Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. (2008) (465)
- Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. (2003) (458)
- Bardoxolone methyl and kidney function in CKD with type 2 diabetes. (2011) (456)
- Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. (2015) (423)
- Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality. (2011) (411)
- Acute Kidney Injury and Mortality in Hospitalized Patients (2012) (392)
- Fabry disease: Guidelines for the evaluation and management of multi-organ system involvement (2006) (384)
- Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy (2009) (319)
- Brief report: Liddle's syndrome revisited--a disorder of sodium reabsorption in the distal tubule. (1994) (318)
- Angiotensin II directly stimulates ENaC activity in the cortical collecting duct via AT(1) receptors. (2002) (293)
- Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure. (1999) (288)
- Long-term risk of mortality and end-stage renal disease among the elderly after small increases in serum creatinine level during hospitalization for acute myocardial infarction. (2008) (280)
- Time-dependent associations between iron and mortality in hemodialysis patients. (2005) (279)
- The global burden of chronic kidney disease: estimates, variability and pitfalls (2017) (277)
- Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease (2015) (266)
- Kidney function and cognitive impairment in US adults: the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. (2008) (262)
- Improving outcomes from acute kidney injury: report of an initiative (2007) (244)
- Association of Chronic Kidney Disease With Atrial Fibrillation Among Adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) Study (2011) (237)
- Effect of Bardoxolone Methyl on Kidney Function in Patients with T2D and Stage 3b–4 CKD (2011) (235)
- Chronic Kidney Disease: A Public Health Problem That Needs a Public Health Action Plan (2006) (226)
- Genetic disorders of renal electrolyte transport. (1999) (222)
- Activation of ion transport systems during cell volume regulation. (1987) (216)
- Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran. (2002) (198)
- Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. (2008) (190)
- Sodium and potassium handling by the aldosterone-sensitive distal nephron: the pivotal role of the distal and connecting tubule. (2004) (188)
- A Meta-analysis of the Association of Estimated GFR, Albuminuria, Diabetes Mellitus, and Hypertension With Acute Kidney Injury. (2015) (184)
- Anionic Phospholipids Regulate Native and Expressed Epithelial Sodium Channel (ENaC)* (2002) (174)
- Global Cardiovascular and Renal Outcomes of Reduced GFR. (2017) (167)
- Racial differences in the prevalence of chronic kidney disease among participants in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Cohort Study. (2006) (161)
- Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation (2011) (145)
- Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN). (2010) (139)
- Mechanisms Contributing to Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus and Stage 4 Chronic Kidney Disease Treated with Bardoxolone Methyl (2014) (137)
- Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry. (2010) (130)
- Evaluation and initial management of acute kidney injury. (2008) (129)
- Parallel adaptation of the rabbit renal cortical sodium/proton antiporter and sodium/bicarbonate cotransporter in metabolic acidosis and alkalosis. (1987) (128)
- Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. (2007) (127)
- Kidney disease in the first-degree relatives of African-Americans with hypertensive end-stage renal disease. (1996) (125)
- Design of clinical trials in acute kidney injury: report from an NIDDK workshop on trial methodology. (2012) (125)
- Dietary patterns and risk of death and progression to ESRD in individuals with CKD: a cohort study. (2014) (123)
- Fibrosis: a key feature of Fabry disease with potential therapeutic implications (2013) (123)
- Prevalence of apparent treatment-resistant hypertension among individuals with CKD. (2013) (122)
- K/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease: Work group membership (2005) (118)
- Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study (2018) (117)
- Parathyroid hormone inhibition of Na+-H+ antiporter activity in a cultured renal cell line. (1986) (117)
- End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry. (2010) (114)
- Chronic Kidney Disease and Risk of Death from Infection (2011) (113)
- Rapid redistribution and inhibition of renal sodium transporters during acute pressure natriuresis. (1996) (113)
- Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease. (2011) (112)
- Angiotensin I Conversion to Angiotensin II Stimulates Cortical Collecting Duct Sodium Transport (2003) (108)
- Screening, diagnosis, and management of patients with Fabry disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. (2017) (108)
- Chloride uptake by brush border membrane vesicles isolated from rabbit renal cortex. Coupling to proton gradients and K+ diffusion potentials. (1981) (108)
- Mixed type inhibition of the renal Na+/H+ antiporter by Li+ and amiloride. Evidence for a modifier site. (1983) (106)
- Simplified citrate anticoagulation for continuous renal replacement therapy. (2001) (106)
- Liddle syndrome: genetics and mechanisms of Na+ channel defects. (2001) (104)
- Improving outcomes of acute kidney injury: report of an initiative (2007) (104)
- Improving outcomes from acute kidney injury. (2007) (103)
- Association of waist circumference and body mass index with all-cause mortality in CKD: The REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study. (2011) (102)
- Predictors of survival in patients with end-stage renal disease evaluated for kidney transplantation. (2007) (102)
- Liddle syndrome: an autosomal dominant form of human hypertension. (1998) (101)
- How well does urinary lyso-Gb3 function as a biomarker in Fabry disease? (2010) (101)
- Measurement of picomole amounts of carbon dioxide by calorimetry. (1975) (100)
- Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry (2016) (100)
- Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients. (2003) (99)
- Blood pressure and amiloride-sensitive sodium channels in vascular and renal cells (2014) (99)
- Waist Circumference, Body Mass Index, and ESRD in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study. (2016) (99)
- Oxidative stress in hypertension and chronic kidney disease: role of angiotensin II. (2004) (97)
- Acute renal failure in the 21st century: recommendations for management and outcomes assessment. (1997) (95)
- Development of a clinical research agenda for acute kidney injury using an international, interdisciplinary, three-step modified Delphi process. (2008) (91)
- Allogeneic Mesenchymal Stem Cells for Treatment of AKI after Cardiac Surgery. (2017) (89)
- Immunolocalization of the Na+/H+exchanger isoform NHE2 in rat kidney. (1998) (88)
- Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults (2008) (86)
- Albuminuria, kidney function, and the incidence of cognitive impairment among adults in the United States. (2011) (86)
- Associations of dietary fat with albuminuria and kidney dysfunction. (2010) (85)
- Foot Process Effacement Is an Early Marker of Nephropathy in Young Classic Fabry Patients without Albuminuria (2014) (84)
- Macula densa Na(+)/H(+) exchange activities mediated by apical NHE2 and basolateral NHE4 isoforms. (2000) (83)
- Poverty and Racial Disparities in Kidney Disease: The REGARDS Study (2010) (82)
- Electrogenic sodium/bicarbonate cotransport in rabbit renal cortical basolateral membrane vesicles. (1986) (82)
- Na+/H+ antiporter of brush border vesicles: studies with acridine orange uptake. (1982) (82)
- Genetic association of 11 beta-hydroxysteroid dehydrogenase type 2 (HSD11B2) flanking microsatellites with essential hypertension in blacks. (1996) (81)
- Rationale and Trial Design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON) (2013) (79)
- Obesity, metabolic health, and the risk of end-stage renal disease (2014) (78)
- Heterologous expression of rat NHE4: a highly amiloride-resistant Na+/H+ exchanger isoform. (1997) (78)
- ATP masks stretch activation of epithelial sodium channels in A6 distal nephron cells. (2002) (77)
- Asymmetric distribution of the Na+/H+ antiporter in the renal proximal tubule epithelial cell. (1983) (77)
- Kidney function, albuminuria, and all-cause mortality in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) study. (2010) (76)
- A roadmap for biomarker qualification (2010) (76)
- Pharmacovigilance and biosimilars: considerations, needs and challenges (2013) (75)
- Kidney measures beyond traditional risk factors for cardiovascular prediction: A collaborative meta-analysis (2015) (75)
- Renal Na+/H+ exchanger isoforms and their regulation by thyroid hormone. (1996) (74)
- Cardiovascular risk factors in CKD associate with both ESRD and mortality. (2013) (74)
- Proton gradients in renal cortex brush-border membrane vesicles. Demonstration of a rheogenic proton flux with acridine orange. (1981) (73)
- Analysis of left ventricular mass in untreated men and in men treated with agalsidase-β: data from the Fabry Registry (2013) (71)
- Correlates of anemia in American blacks and whites: the REGARDS Renal Ancillary Study. (2008) (69)
- Age-specific association of reduced estimated glomerular filtration rate and albuminuria with all-cause mortality. (2011) (69)
- Age-specific associations of reduced estimated glomerular filtration rate with concurrent chronic kidney disease complications. (2011) (68)
- Interaction of Syntaxins with the Amiloride-sensitive Epithelial Sodium Channel* (1999) (68)
- Agalsidase-Beta Therapy for Advanced Fabry Disease A Randomized Trial (2006) (65)
- Albuminuria and racial disparities in the risk for ESRD. (2011) (65)
- Familial hyperkalemic hypertension: phenotypic analysis in a large family with the WNK1 deletion mutation. (2003) (65)
- Mutational analysis of transmembrane histidines in the amiloride-sensitive Na+/H+ exchanger. (1995) (62)
- A validated disease severity scoring system for Fabry disease. (2010) (61)
- Effects of anion-transport inhibitors on NaCl reabsorption in the rat superficial proximal convoluted tubule. (1979) (61)
- Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry. (2015) (59)
- Effect of acetazolamide on bicarbonate reabsorption in the proximal tubule of the rat. (1979) (58)
- Contrasting Cholesterol Management Guidelines for Adults with CKD. (2015) (57)
- Anti-α-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry Registry. (2012) (57)
- Chronic use of sodium ferric gluconate complex in hemodialysis patients: safety of higher-dose (> or =250 mg) administration. (2003) (56)
- Liddle's disease: abnormal regulation of amiloride-sensitive Na+ channels by beta-subunit mutation. (1996) (56)
- QT Prolongation Is an Independent Predictor of Mortality in End‐Stage Renal Disease (2010) (55)
- Ion transport processes in apical membranes of epithelia. (1984) (55)
- Localization and functional characterization of Na+/H+ exchanger isoform NHE4 in rat thick ascending limbs. (2001) (54)
- Fabry disease: diagnosis and management, with emphasis on the renal manifestations (2005) (54)
- Increased Vmax for Na+/H+ antiporter activity in proximal tubule brush border vesicles from rabbits with metabolic acidosis. (1984) (53)
- Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase (2015) (53)
- Stretch modulates amiloride sensitivity and cation selectivity of sodium channels in human B lymphocytes. (1996) (52)
- Low income and albuminuria among REGARDS (Reasons for Geographic and Racial Differences in Stroke) study participants. (2012) (52)
- Inflammation biomarkers and risk of all-cause mortality in the Reasons for Geographic And Racial Differences in Stroke cohort. (2011) (52)
- Sulfenic Acid Modification of Endothelin B Receptor is Responsible for the Benefit of a Nonsteroidal Mineralocorticoid Receptor Antagonist in Renal Ischemia. (2016) (52)
- Evidence for an amiloride-insensitive Na+/H+ exchanger in rat renal cortical tubules. (1997) (52)
- Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy (2015) (51)
- Autophagy-lysosome pathway associated neuropathology and axonal degeneration in the brains of alpha-galactosidase A-deficient mice (2014) (51)
- Design of clinical trials in acute kidney injury: a report from an NIDDK workshop--prevention trials. (2012) (49)
- Cloning, sequencing, and expression of Na(+)-H+ antiporter cDNAs from human tissues. (1992) (49)
- Hemoglobin Concentration and Risk of Incident Stroke in Community-Living Adults (2016) (49)
- Deletion of mineralocorticoid receptors in smooth muscle cells blunts renal vascular resistance following acute cyclosporine administration. (2016) (49)
- Prevalence and characteristics of a family history of end-stage renal disease among adults in the United States population: Reasons for Geographic and Racial Differences in Stroke (REGARDS) renal cohort study. (2007) (48)
- Acute hyperkalemia associated with inhalation of a potent ENaC antagonist: Phase 1 trial of GS-9411. (2014) (48)
- Risk for recurrent coronary heart disease and all-cause mortality among individuals with chronic kidney disease compared with diabetes mellitus, metabolic syndrome, and cigarette smokers. (2013) (48)
- NaCl entry mechanisms in the luminal membrane of the renal tubule. (1982) (48)
- Late breaking clinical trials 1 (2011) (48)
- Synergistic protective effects of erythropoietin and olmesartan on ischemic stroke survival and post-stroke memory dysfunctions in the gerbil (2006) (47)
- Physical and Psychological Burden of Chronic Kidney Disease among Older Adults (2010) (46)
- Comparison of absolute serum creatinine changes versus Kidney Disease: Improving Global Outcomes consensus definitions for characterizing stages of acute kidney injury. (2013) (46)
- G-proteins modulate amiloride-sensitive sodium channels. (1994) (46)
- Towards a definition and classification of acute kidney injury. (2005) (46)
- Incident ESRD and treatment-resistant hypertension: the reasons for geographic and racial differences in stroke (REGARDS) study. (2014) (46)
- Regulation by PKC isoforms of Na+/H+exchanger in luminal membrane vesicles isolated from cortical tubules. (1999) (45)
- Improving Outcomes from Acute Kidney Injury (AKI): Report on an Initiative (2007) (44)
- Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints (2019) (43)
- Past Decline Versus Current eGFR and Subsequent Mortality Risk. (2016) (43)
- Gastrointestinal involvement in Fabry disease. So important, yet often neglected (2016) (43)
- Current and Investigational Therapeutics for Fabry Disease (2019) (43)
- Immunolocalization of the Na+/H+ exchanger isoform NHE2 in rat kidney. (1998) (43)
- Blood pressure indexes and end-stage renal disease risk in adults with chronic kidney disease. (2012) (42)
- High-Sensitivity C-Reactive Protein and Risk of Sepsis (2013) (41)
- Hydrogen ion transport in epithelia (1984) (41)
- Urinary Podocyte Loss Is Increased in Patients with Fabry Disease and Correlates with Clinical Severity of Fabry Nephropathy (2016) (40)
- Association of Reduced eGFR and Albuminuria with Serious Fall Injuries among Older Adults. (2016) (40)
- Validation study of medicare claims to identify older US adults with CKD using the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. (2015) (40)
- Urinary acidification: CO2 transport by the rabbit proximal straight tubule. (1977) (39)
- Association between urinary albumin excretion and coronary heart disease in black vs white adults. (2013) (39)
- Isolation and characterization of luminal and basolateral plasma membrane vesicles from the medullary thick ascending loop of Henle. (1996) (38)
- Nondisease-specific problems and all-cause mortality among older adults with CKD: the REGARDS Study. (2014) (38)
- Healthy Behaviors, Risk Factor Control and Awareness of Chronic Kidney Disease (2013) (38)
- Amiloride-sensitive sodium conductance in human B lymphoid cells. (1993) (38)
- Pharmacokinetics of esmolol and ASL‐8123 in renal failure (1989) (37)
- Chromosomal localization of angiotensin II type 1 receptor isoforms in the rat. (1993) (37)
- Incidence of stroke symptoms among adults with chronic kidney disease: results from the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. (2012) (37)
- Geographic variation in CKD prevalence and ESRD incidence in the United States: results from the reasons for geographic and racial differences in stroke (REGARDS) study. (2013) (36)
- Use of a rare disease registry for establishing phenotypic classification of previously unassigned GLA variants: a consensus classification system by a multispecialty Fabry disease genotype–phenotype workgroup (2020) (36)
- Design of clinical trials in AKI: a report from an NIDDK workshop. Trials of patients with sepsis and in selected hospital settings. (2012) (36)
- Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease (2008) (36)
- The Fabry cardiomyopathy: models for the cardiologist. (2011) (35)
- K-Cl transport systems in rabbit renal basolateral membrane vesicles. (1987) (35)
- Racial differences in albuminuria, kidney function, and risk of stroke (2012) (34)
- Chronic Kidney Disease Is Often Unrecognized among Patients with Coronary Heart Disease: The REGARDS Cohort Study (2008) (34)
- Arrhythmias in Fabry Cardiomyopathy (2012) (34)
- Mineralocorticoid receptor blockers and chronic kidney disease. (2009) (34)
- Prevalence of chronic kidney disease and anemia among participants in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Cohort Study: baseline results. (2005) (33)
- Carbonic anhydrase-dependent bicarbonate reabsorption in the rat proximal tubule. (1979) (33)
- Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry. (2016) (33)
- Survival advantage of black patients with kidney disease after acute myocardial infarction. (2006) (33)
- Nephropathy in Fabry disease: the importance of early diagnosis and testing in high-risk populations. (2009) (32)
- Disorders of the Epithelial Na+ Channel in Liddle’s Syndrome and Autosomal Recessive Pseudohypoaldosteronism Type 1 (2000) (31)
- Electrically neutral Na+-H+ exchange in endosomes obtained from rabbit renal cortex. (1986) (31)
- Association of inflammatory and endothelial cell activation biomarkers with acute kidney injury after sepsis (2014) (30)
- The A563T variation of the renal epithelial calcium channel TRPV5 among African Americans enhances calcium influx. (2009) (30)
- Oral Anticoagulants and Risk of Nephropathy (2015) (30)
- The human angiotensinase C gene (HUMPCP) maps to 11q14 within 700 kb of D11S901: a candidate gene for essential hypertension. (1997) (30)
- Sodium ferric gluconate complex in haemodialysis patients: a prospective evaluation of long-term safety. (2004) (29)
- Cyclosporine inhibits the renal response to L-arginine in human kidney transplant recipients. (1995) (29)
- An intermediate-conductance Ca2+-activated K+ channel mediates B lymphoma cell cycle progression induced by serum (2007) (29)
- K-Cl cotransport systems. (1989) (28)
- Warfarin-related nephropathy: another newly recognized complication of an old drug. (2011) (28)
- Analysis of the genetic contamination of salt-sensitive Dahl/Rapp rats. (1994) (28)
- Ion selectivity and proximal salt reabsorption. (1978) (27)
- Peptide block of constitutively activated Na+ channels in Liddle's disease. (1996) (27)
- Intramuscular chlorpromazine and creatine kinase: acute psychoses or local muscle trauma? (1969) (27)
- Liddle syndrome: clinical and cellular abnormalities. (1994) (26)
- Cloning and functional studies of splice variants of the α-subunit of the amiloride-sensitive Na+ channel. (1998) (26)
- Blood Pressure, Proteinuria and Nephropathy in Fabry Disease (2010) (26)
- IgA nephropathy in blacks: studies of IgA2 allotypes and clinical course. (1991) (25)
- Cytosolic pH sensitivity of an expressed human NHE-1 Na(+)-H+ exchanger. (1993) (25)
- Use of diuretics in the treatment of cirrhotic ascites. (1983) (25)
- Steroids and Exogenous γ-ENaC Subunit Modulate Cation Channels Formed by α-ENaC in Human B Lymphocytes* (2004) (25)
- Enzyme replacement therapy and Fabry nephropathy. (2010) (25)
- Interactions of chloride and amiloride with the renal Na+/H/ antiporter. (1988) (24)
- A Distinct Urinary Biomarker Pattern Characteristic of Female Fabry Patients That Mirrors Response to Enzyme Replacement Therapy (2011) (24)
- Renal genetic disorders related to K+ and Mg2+. (2002) (24)
- Prevalence and prognosis of unrecognized myocardial infarctions in chronic kidney disease. (2012) (24)
- Proton secretion by the kidney. (1979) (23)
- WNK4-mediated regulation of renal ion transport proteins. (2007) (23)
- Low-renin and nonmodulating essential hypertension. (1999) (23)
- Involvement of renal apical Na transport systems in the control of blood pressure. (2001) (23)
- The role of cystatin-C in the confirmation of reduced glomerular filtration rate among the oldest old (2016) (22)
- Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease. (2019) (22)
- Genetic forms of human hypertension (2001) (22)
- Critical care nephrology: management of acid-base disorders with CRRT. (2012) (22)
- Blood Pressure and Metabolic Effects of Acetyl-l-Carnitine in Type 2 Diabetes: DIABASI Randomized Controlled Trial (2018) (22)
- Metabolic subtypes and risk of mortality in normal weight, overweight, and obese individuals with CKD. (2013) (22)
- Racial differences in the competing risks of mortality and ESRD after acute myocardial infarction. (2008) (21)
- Renal apical membrane sodium-hydrogen exchange in genetic salt-sensitive hypertension. (1994) (21)
- Immunopurification and functional reconstitution of a Na+ channel complex from rat lymphocytes. (1995) (21)
- Membrane Tension Modulates the Effects of Apical Cholesterol on the Renal Epithelial Sodium Channel (2007) (21)
- The natural history of fabry disease (2010) (21)
- Low Hemoglobin Levels and Recurrent Falls in U.S. Men and Women: Prospective Findings from the REasons for Geographic And Racial Differences in Stroke (REGARDS) Cohort (2013) (21)
- Rapid, proteomic urine assay for monitoring progressive organ disease in Fabry disease (2019) (20)
- Diagnosis and management of kidney involvement in Fabry disease. (2006) (20)
- Genetic disorders of potassium homeostasis. (2013) (20)
- Significant improvement in Fabry disease podocytopathy after 3 years of treatment with agalsidase beta (2016) (20)
- Expression of the amiloride-sensitive sodium channel beta subunit gene in human B lymphocytes. (1997) (20)
- Membranous glomerulopathy in an adult patient with X-linked agammaglobulinemia receiving intravenous gammaglobulin. (2011) (20)
- Renal Manifestations of Fabry Disease (2010) (20)
- The amiloride-sensitive endothelial sodium channel and vascular tone. (2013) (19)
- Serum Creatinine Trajectories for Community- versus Hospital-Acquired Acute Kidney Injury (2016) (19)
- Association of family history of ESRD, prevalent albuminuria, and reduced GFR with incident ESRD. (2012) (19)
- Genetic renal tubular disorders of renal ion channels and transporters. (2001) (19)
- Fabry disease: dose matters. (2014) (19)
- Cardiomyopathy and Response to Enzyme Replacement Therapy in a Male Mouse Model for Fabry Disease (2012) (18)
- Estimated Glomerular Filtration Rate: Fit for What Purpose? (2016) (18)
- Effects of chloride gradients on total CO2 flux in the rabbit cortical collecting tubule. (1983) (18)
- Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease (2021) (18)
- Enzyme replacement therapy and Fabry kidney disease: quo vadis? (2007) (18)
- Renal sodium handling: the role of the epithelial sodium channel. (2005) (17)
- Anion permeabilities of the isolated perfused rabbit proximal tubule. (1982) (17)
- Urinary Tubular Injury Biomarkers Are Associated With ESRD and Death in the REGARDS Study (2018) (17)
- The effects of nicardipine in hypertensive subjects with impaired renal function (1986) (16)
- Association of duration of residence in the southeastern United States with chronic kidney disease may differ by race: the REasons for Geographic and Racial Differences in Stroke (REGARDS) cohort study (2013) (16)
- Interaction of syntaxins with epithelial ion channels (2000) (16)
- Na+/H+ antiporter in membrane populations resolved from a renal brush border vesicle preparation. (1984) (15)
- Liddle’s syndrome: Heritable human hypertension caused by mutations in the ß subnit of the epithelial sodium channel (1995) (15)
- Improving outcomes of acute kidney injury: report of an initiative. (2007) (15)
- Cloning and functional studies of splice variants of the alpha-subunit of the amiloride-sensitive Na+ channel. (1998) (15)
- Acute kidney injury in sepsis: questions answered, but others remain. (2010) (15)
- Polymorphism in the beta subunit and Na+ transport. (1996) (15)
- Hemoglobin concentration and cognitive impairment in the renal REasons for Geographic And Racial Differences in Stroke (REGARDS) Study. (2010) (15)
- Rapid Immunochromatographic Detection of Serum Anti-α-Galactosidase A Antibodies in Fabry Patients after Enzyme Replacement Therapy (2015) (14)
- Risks for All-Cause Mortality: Stratified by Age, Estimated Glomerular Filtration Rate and Albuminuria (2017) (14)
- Sodium uptake mechanisms in brush-border membrane vesicles prepared from rabbit renal cortex. (1982) (13)
- Genetic forms of renal potassium and magnesium wasting. (2002) (13)
- WNK kinases, distal tubular ion handling and hypertension. (2003) (13)
- Delay in time to receipt of thrombolytic medication among Medicare patients with kidney disease. (2005) (13)
- Late onset variants in Fabry disease: Results in high risk population screenings in Argentina (2015) (13)
- Prevention, protection, and the intrarenal renin-angiotensin systems. (2001) (12)
- The Furosemide Stress Test and Predicting AKI Outcomes. (2015) (12)
- Occupancy of aldosterone binding sites in rat kidney cytosol (1978) (12)
- Liddle's syndrome: a public health menace? (1995) (12)
- Acidification in the in vitro perfused tubule. (1982) (12)
- Competing risks: you only die once. (2016) (12)
- The epithelial sodium channel in hypertension (1999) (12)
- Pathophysiology and treatment of resistant hypertension: the role of aldosterone and amiloride-sensitive sodium channels. (2014) (12)
- Acute kidney injury: where's the consensus about its definition? (2010) (11)
- Liddle's syndrome: genetics and mechanisms of Na+ channel defects. (2001) (11)
- Early indicators of disease progression in Fabry disease that may indicate the need for disease-specific treatment initiation: findings from the opinion-based PREDICT-FD modified Delphi consensus initiative (2020) (11)
- Steroids and exogenous gamma-ENaC subunit modulate cation channels formed by alpha-ENaC in human B lymphocytes. (2004) (11)
- Similar Names for Similar Biologics (2014) (11)
- T594M mutation in the ENaC β subunit and low-renin hypertension in blacks (1999) (11)
- Serum albumin concentration and risk of end-stage renal disease: the REGARDS study (2018) (11)
- Conjunctival lymphangiectasia associated with classic Fabry disease (2017) (10)
- Interventional nephrology: work in progress. (2003) (10)
- Categories of Hospital-Associated Acute Kidney Injury: Time Course of Changes in Serum Creatinine Values (2015) (10)
- Drug Insight: safety of intravenous iron supplementation with sodium ferric gluconate complex (2006) (10)
- Aldosterone-related genetic effects in hypertension (2000) (10)
- Relationship of diastolic blood pressure with cyclic GMP excretion among young adults (the CARDIA study): influence of a family history of hypertension (1997) (9)
- Low renin hypertension in the next millennium. (2000) (9)
- Acute renal failure in the 21st century (1997) (9)
- Introduction to Vitamin D Symposium, March 14, 2008. (2008) (9)
- Uremic acidosis. (1988) (9)
- Cognitive function in adults aging with fabry disease: a case-control feasibility study using telephone-based assessments. (2015) (8)
- Acidic ATP activates lymphocyte outwardly rectifying chloride channels via a novel pathway (2004) (7)
- αENaC: leading the charge (1999) (7)
- Nitric oxide and Bartter and Gitelman syndromes. (2001) (7)
- Distinct epitopes on amiloride. (1989) (7)
- Inclusion of albumin as a target in therapy guidelines: guidelines for chronic kidney disease. (2004) (7)
- Mechanism of H+ secretion in the proximal convoluted tubule. (1990) (7)
- An Alu cassette in the human epithelial sodium channel. (2001) (7)
- N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline, amiloride analogues, and renal Na+/H+ antiporter. (1987) (6)
- Amiloride-Sensitive Na+ Transport Mechanisms (1992) (6)
- Contribution of leaked load to solute transport by renal tubules. (1978) (6)
- Accessory factors and the regulation of epithelial sodium channel activity. (1999) (6)
- Inverse Relationship of Urinary Cyclic GMP to Blood Pressure Reactivity in the CARDIA Study: Vasodilatory Regulation of Sympathetic Vasoconstriction (1998) (6)
- P24—Prognostic Indicators of Renal Disease Progression: Natural History Data From the Fabry Registry (2012) (6)
- Clinical Trials during the SARS-CoV-2 Pandemic (2020) (6)
- Exploration of anaemia as a progression factor in African Americans with cardiovascular disease. (2009) (5)
- Standardising clinical outcomes measures for adult clinical trials in Fabry disease: A global Delphi consensus. (2021) (5)
- Effects of Bardoxolone Methyl on Magnesium in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease (2019) (5)
- T594M mutation in the ENaC beta subunit and low-renin hypertension in blacks. (1999) (5)
- A phase 2a study to investigate the effect of a single dose of migalastat HCl, a pharmacological chaperone, on agalsidase activity in subjects with Fabry disease (2013) (4)
- Amiloride: the "new" renal tonic? (2015) (4)
- Vascular grafts for hemodialysis: types, sites and techniques. (2004) (4)
- X-inactivation modifies disease severity in female carriers of murine X-linked Alport syndrome (2010) (4)
- HUS and diabetic nephropathy (2012) (4)
- Accumulation of weak base in gastric mucosa provides evidence for an acidic storage compartment. (1989) (4)
- Sticky business: cytoskeleton and Na+ transport. (1996) (4)
- Evaluating and treating intractable cough. (1985) (4)
- Regulation of the Activity of the Na+‐H+ Antiporter in Brush‐Border Membrane Vesicles from the Proximal Tubule a (1985) (3)
- 427 RACIAL DIFFERENCES IN SURVIVAL AFTER ACUTE MYOCARDIAL INFARCTION ACCORDING TO KIDNEY FUNCTION (2005) (3)
- Diseases of the kidney (Ed 6): Authors: Robert W. Schrier, MD, and Carl W. Gottschalk, MD Publisher: Little, Brown and Company (1997) (3)
- Improvement of blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. (2005) (3)
- The pressing need for real-time risk assessment of hospital-acquired acute kidney injury. (2016) (3)
- Macula densa Na 1 / H 1 exchange activities mediated by apical NHE 2 and basolateral NHE 4 isoforms (2000) (3)
- Comparison of Static and Dynamic Baseline Creatinine Surrogates for Defining Acute Kidney Injury (2021) (3)
- FP110A PHASE 2 TRIAL OF THE SAFETY AND EFFICACY OF BARDOXOLONE METHYL IN PATIENTS WITH RARE CHRONIC KIDNEY DISEASES (2018) (3)
- A meta-analysis of the association of estimated GFR, albuminuria, diabetes mellitus, and hypertension with AKI (2015) (3)
- Enzyme replacement therapy for Fabry's disease (2010) (3)
- The Fault Is Not in Our Stars but May Be in Our Embryos: Glomerular Number in Low Birth Weight Babies (2017) (2)
- The effects of cycloheximide on Na+/H+ antiporter activity in cultured opossum kidney cells. (1987) (2)
- PRX-102 for treating Fabry disease: immunogenicity and PK results from a phase 1-2 study (2017) (2)
- Introduction to Focus on Fabry nephropathy: biomarkers, progression, and disease severity. (2010) (2)
- Biologic Regulation of Na/H Antiporter Activity in a Cultured Kidney Cell Line: Effects of Parathyroid Hormone (PTH) (1985) (2)
- Is Cystatin C a promising marker of renal function, at birth, in neonates prenatally diagnosed with congenital kidney anomalies? (2012) (2)
- Treatment of hyperuricemia and gout. (1979) (2)
- A new approach to identifying patients with elevated risk for Fabry disease using a machine learning algorithm (2021) (2)
- Few females develop anti-α-galactosidase A IgG antibodies in response to agalsidase beta treatment: data from the Fabry Registry (2011) (2)
- Regulation of endosomal acidification via Gi-type protein. (1999) (2)
- Development and validation of a self-assessment tool for albuminuria: results from the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. (2011) (2)
- Epithelial sodium channels expressed in Xenopus oocytes are activated by cyclic-AMP (2002) (2)
- Prospective safety study of bardoxolone methyl in patients with type 2 diabetes mellitus, end-stage renal disease and peritoneal dialysis. (2012) (2)
- Autophagy-lysosome pathway associated neuropathology and axonal degeneration in the brains of alpha-galactosidase A-deficient mice (2014) (1)
- 144. Fabry nephropathy (FN) and the agalsidase beta and ARBs and ACE inhibitor treatment (FAACET) study: Determinants of proteinuria during the titration phase (2010) (1)
- FP805PROGRESSION OF NEPHROPATHY IN FABRY PATIENTS RECEIVING ENZYME REPLACEMENT THERAPY (ERT); RELATION TO ANTI-DRUG ANTIBODY (ADA) STATUS AND PROTEINURIA (2018) (1)
- Vitamin D receptor activation: implications for daily practice. (2011) (1)
- Expression of transfected human Na+/H+ exchanger (NHE‐1) in the basolateral membrane of opossum kidney cells (1999) (1)
- Effects of Frequent In-Center Hemodialysis: The Frequent Hemodialysis Network (FHN) Daily Trial (2010) (1)
- The effect of an oral contraceptive on urinary gonadotrophin in women at mid-cycle. (1966) (1)
- Anti-proteinuric therapy and Fabry nephropathy; factors associated with preserved kidney function during agalsidase-beta therapy (2016) (1)
- Hyperkalemia after the publication of RALES. (2004) (1)
- Enzyme Replacement Therapy and Fabry Kidney Disease (2007) (1)
- Clinical benefits of early treatment with Fabrazyme in Fabry disease (2007) (1)
- Optimizing treatment to reach therapeutic goals in fabry disease (2009) (1)
- Dietary Oxidative Balance Scores and Biomarkers of Inflammation among Individuals with and without Chronic Kidney Disease (2018) (1)
- 43: HIGH-SENSITIVITY C-REACTIVE PROTEIN AND RISK OF SEPSIS (2012) (1)
- FO022BARDOXOLONE METHYL PREVENTS EGFR DECLINE IN PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 4 AND TYPE 2 DIABETES - POST-HOC ANALYSES FROM BEACON (2018) (1)
- CORE CURRICULUM IN NEPHROLOGY Hypertension (2004) (1)
- 94: Arrhythmias and Implantable Cardioverter Defibrillators in Fabry Cardiomyopathy (2009) (1)
- Contents Vol. 8, 2000 (2000) (1)
- Regulation of the Na+ /H+ Antiporter in Cells of the Proximal Tubule (1984) (1)
- Plasmids and pestilence--biological and clinical aspects of bubonic plague. (1986) (1)
- Analysis of the baseline characteristics of Fabry disease patients screened for the pegunigalsidase alfa phase III BALANCE study (2019) (1)
- Evaluation of Renal Function and Renal Risk in the Twenty-First Century (2017) (1)
- Hereditary disorders of potassium homeostasis. (2003) (1)
- Epilogue: UAB Symposium November 2015 (2016) (1)
- Fabry Nephropathy : Biomarkers , Progression and Treatment Opportunities (2017) (1)
- ROLE OF ANION TRANSPORT MECHANISMS IN PROXIMAL TUBULE ACIDIFICATION (1981) (1)
- AlphaENaC: leading the charge. (1999) (1)
- 6th Update on Fabry Disease: Biomarkers, Progression and Treatment Opportunities (2019) (1)
- Appendiceal tissue confirmation of Fabry's disease. (2015) (1)
- Study of Black-White Differences in Anemia Prevalence in the United States: The Reasons for Geographic and Racial Differences in Stroke Study. (2006) (0)
- Conjunctival lymphangiectasias and cysts persist despite long-term enzyme replacement therapy in males with Fabry disease (2015) (0)
- Estimation of arrhythmia risk in patients with Fabry disease using a machine learning model (2023) (0)
- CLINICAL ACUTE KIDNEY INJURY 1 (2014) (0)
- Neuropathic pain in young males with Fabry disease: indication for enzyme replacement therapy supported by renal biopsy findings even with "normal" kidney function measurements (2014) (0)
- Disease : Improving Global Outcomes ” ( KDIGO ) Screening , diagnosis , and management of patients with Fabry disease : conclusions from a “ Kidney Controversies Conference (0)
- Pedigree analysis: A call to action to raise awareness of Fabry disease and the importance of family history evaluation (2015) (0)
- Original Investigation Incident ESRD and Treatment-Resistant Hypertension: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study (2014) (0)
- Association Between Urinary Albumin Excretion and Coronary Heart Disease in Black vsWhite Adults (2013) (0)
- Fabry disease: Late onset variant in proteinuria and dialysis screening: Be prepared for more cases, and more questions (2015) (0)
- Contents Vol. 139, 2018 (2018) (0)
- Long-term safety and efficacy of pegunigalsidase alfa administered every 4 weeks in patients with Fabry disease: Two-year interim results from the ongoing phase 3 BRIGHT51 open-label extension study (2023) (0)
- Diabetes, Dietary Protein and Glomerular Hyperfiltration (2004) (0)
- Sulfenic acid modification of ETB receptor is responsible for the benefit of a non-steroidal MR antagonist in renal ischemia (2018) (0)
- Cloning and functional studies of splice variants of the a-subunit of the amiloride-sensitive Na 1 channel (1998) (0)
- channels in A6 distal nephron cells ATP masks stretch activation of epithelial sodium (2016) (0)
- Validation of an Albuminuria Self-assessment Tool in the Multi-Ethnic Study of Atherosclerosis. (2015) (0)
- Risk Factors for Incident CKD in Black and White Americans: The REGARDS Study. (2023) (0)
- Medical Staff Conference Exercise and Coronary Artery Disease What Should We Be Recommending to Our Patients (and Ourselves)? (2005) (0)
- Contents Vol. 136, 2017 (2017) (0)
- Targeting Glycosphingolipid Metabolism to Treat Kidney Disease (2016) (0)
- transplantation Chronic kidney disease : including end-stage renal disease requiring renal replacement therapy with dialysis or renal transplantation Stroke or transient ischemic attacks Deafness , of acute or chronic onset R Schiffmann (0)
- 650: BIOMARKERS OF INFLAMMATION, ENDOTHELIAL CELL ACTIVATION, AND CHRONIC KIDNEY FUNCTION AND LONG TERM RISK OF ACUTE KIDNEY INJURY AFTER SEPSIS (2012) (0)
- CHANGES IN PLASMA NITRIC OXIDE METABOLITE LEVELS DURING STRESS ARE INVERSELY RELATED TO BLOOD PRESSURE REACTIVITY IN PREMENOPAUSAL BUT NOT POSTMENOPAUSAL WOMEN (1998) (0)
- P23—New Guidelines for the Evaluation and Management of Fabry Disease in Children (2012) (0)
- Membranous Glomerulonephritis in an Individual with X-linked Agammaglobulinemia on Intravenous Immunoglobulin (2006) (0)
- Male patients with Fabry disease treated with enzyme replacement therapy: Renal progression rates reflect averaged urine protein to creatinine ratios (2016) (0)
- Utilization of artificial intelligence to identify undiagnosed Fabry patients: Development of a validated machine learning model (2021) (0)
- SP017MALE FABRY PATIENTS TREATED WITH ENZYME REPLACEMENT THERAPY: RENAL PROGRESSION RATES REFLECT AVERAGED URINE PROTEIN TO CREATININE RATIOS (2015) (0)
- Contents Vol. 142, 2019 (2019) (0)
- Managing Patients With Chronic Kidney Disease (2012) (0)
- 143. End stage renal disease in patients with Fabry disease: Natural history data from the Fabry registry (2010) (0)
- Core curriculum in nephrologyHypertension (2004) (0)
- Abstract 13396: The Association Between Oxidative Balance Score and Elevated C-Reactive Protein in the Reasons for Geographic and Racial Differences in Stroke Cohort (2012) (0)
- 735: OBESITY AND RISK OF SEPSIS (2012) (0)
- Understanding and modifying Fabry disease: Rationale and design of a pivotal Phase 3 study and results from a patient-reported outcome validation study (2022) (0)
- Comparisons of estimated GFR and Cockcroft Gault equations: calibration against relative risk for all-cause mortality. (2016) (0)
- Introduction to the third annual rostand vitamin D symposium. (2009) (0)
- Occurrence of severe clinical events by time on agalsidase beta among patients with Fabry disease (2015) (0)
- 27. Nephropathy in Fabry disease: Baseline characteristics of 1262 patients in the Fabry Registry (2008) (0)
- Therapeutic Dilemmas in Type 11 Diabetes Mellitus-Improving and Maintaining fl-Cell and Insulin Sensitivity (0)
- Progressive development of microalbuminuria and proteinuria in males and females with fabry disease (2007) (0)
- FP152EFFECT OF BARDOXOLONE METHYL TREATMENT ON URINARY ALBUMIN IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE - POST-HOC ANALYSIS FROM BEAM AND BEACON (2018) (0)
- Phenotypic characterization of a four-generation pedigree with the A143T Fabry mutation (2014) (0)
- 2018 Stroke August 2016 hemoglobin concentration with incident stroke events among participants enrolled in the Reasons for Geographic and Racial Differences in Stroke (2016) (0)
- 232: Phase 2b/3 Trial Design and Baseline Patient Characteristics of a Study to Determine Effects of Bardoxolone Methyl (BARD) in Patients With Type 2 Diabetes (T2DM) and Chronic Kidney Disease (CKD) (2010) (0)
- Genetic diseases / Molecular mechanisms (2011) (0)
- 8. How useful is urinary lyso-Gb3 as a biomarker for Fabry disease? (2010) (0)
- Elucidating the toxic effect and disease mechanisms associated with Lyso-Gb3 in Fabry disease. (2023) (0)
- CNS Neuropathology in a Mouse Model of Fabry Disease Indicates Alterations in the Autophagy-Lysosome Pathway (2012) (0)
- Risk factors for severe clinical events and the incidence of these events in male and female patients with Fabry disease treated with agalsidase beta (2015) (0)
- Front & Back Matter (2015) (0)
- First results of a head-to-head trial of pegunigalsidase alfa vs. agalsidase beta in Fabry disease: 2 year results of the phase 3 randomized, double-blind, BALANCE study (2023) (0)
- Original Investigation A Meta-analysis of the Association of Estimated GFR, Albuminuria, Diabetes Mellitus, and Hypertension With Acute Kidney Injury (2015) (0)
- to reduced GFR (2017) (0)
- MO026IMPROVED ACUTE KIDNEY INJURY (AKI) STAGING WITH SERUM CREATININE TRAJECTORIES (2017) (0)
- Contents Vol. 143, 2019 (2019) (0)
- Worldwide cardiovascular and ESRD outcomes attributable to reduced GFR Running Title: Reduced GFR-attributed health loss (2018) (0)
- Sodium transporters in health and disease (1997) (0)
- Disclosure Statement Editorial Board (2019) (0)
- A survivor analysis for major clinical events in heterozygous female patients with Fabry disease using group consensus phenotype classifications from hemizygous male patients (2018) (0)
- Enhanced pharmacokinetics profile of pegunigalsidase alfa (PRX-102) supports once-monthly 2mg/kg dosing for the treatment of Fabry disease (2018) (0)
- Abstract 55: Kidney Measures Beyond Conventional Risk Factors for Predicting Incident Cardiovascular Disease: A Collaborative Meta-Analysis of 16 Cohorts (2014) (0)
- Front & Back Matter (2015) (0)
- Abstract MP69: Prevalence of Treatment Resistant Hypertension Among Individuals with Chronic Kidney Disease: Results from the REasons for Geographic and Racial Differences in Stroke (REGARDS) Study (2013) (0)
- Medical Saffl Biochemical and Clinical Aspects of Amyloidosis (0)
- Estimation of stroke risk in patients with Fabry disease using a machine learning model (2023) (0)
- 251: Prevalence and Significance of Unrecognized Myocardial Infarctions in Chronic Kidney Disease (2010) (0)
- The development of a multiplexed, rapid, mass spectrometry-based test for new and existing biomarkers to identify and monitor kidney disease in pediatric Fabry disease patients (2015) (0)
- Contents Vol. 131, 2015 (2016) (0)
- Contents Vol. 39, 2014 (2014) (0)
- Contents Vol. 141, 2019 (2019) (0)
- A Fabry genotype-phenotype working group initiative: classifying GLA mutations for male patients in the Fabry Registry (2017) (0)
- Contents Vol. 138, 2018 (2018) (0)
- Immunodissection and electrophysiological examination of cortical collecting duct cells from rat kidney (1994) (0)
- 106. Natural history of Fabry disease: Progression of the nephropathy in a large series of affected males and heterozygous females (2008) (0)
- Regulation by PKC isoforms of Na(+)/H(+) exchanger in luminal membrane vesicles isolated from cortical tubules. (1999) (0)
- Stratifying Risk After a Myocardial Infarction (2004) (0)
- 346 Progression of Chronic Kidney Disease (CKD) in Adult Male Fabry Patients Treated With Enzyme Replacement Therapy (ERT) (2011) (0)
- Subject Index Vol. 8, 2000 (2000) (0)
- Leukaemia-antigen detection. (1971) (0)
- Medical Staff Conference Stress and Medical Training (2005) (0)
- 7th Update on Fabry Disease: Biomarkers, Progression and Treatment Opportunities in 2022 (2022) (0)
- Rationale and design of the MODIFY study: A phase 3 multicenter, double-blind, randomized, placebo-controlled, parallel-group study to determine the efficacy and safety of lucerastat oral monotherapy in adult subjects with Fabry disease (2020) (0)
- Relationship between chronic renal disease, blood pressure, and left ventricular hypertrophy in males and females with Fabry disease (2007) (0)
- FP801IMPACT OF ACUTE KIDNEY INJURY SCREENING DURING PRENATAL CARE VISITS IN SENEGALESE WOMEN: A CLUSTER RANDOMIZED TRIAL (2018) (0)
- Clinical event status of patients with Fabry disease after long-term treatment with agalsidase beta and follow-up from The Fabry Registry (2013) (0)
- Abstract 1571: Association of Chronic Kidney Disease With Atrial Fibrillation in the United States (2009) (0)
- SP023CLASSIFICATION OF MALE FABRY PATIENTS: VALIDATION OF GROUP CONSENSUS BY SURVIVOR ANALYSIS FOR MAJOR CLINICAL EVENTS (2017) (0)
- Pegunigalsidase alfa, a novel PEGylated ERT, evaluated in Fabry disease patients with progressing kidney disease, RCT study design (2020) (0)
- Contents Vol. 137, 2017 (2017) (0)
- Abstract P296: Age-related Differences in Risk Factors for Mortality Among Individuals with Chronic Kidney Disease: The REGARDS Study (2014) (0)
- Similar Names for Similar Biologics (2014) (0)
- A 10-year study documenting the long-term effectiveness of agalsidase-beta treatment in 52 adult patients with classic Fabry disease (2015) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With David G. Warnock?
David G. Warnock is affiliated with the following schools:
